Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan has released some very significant survival data about a previously reported, double-blind, randomized, multicenter phase 3 trial. This trial compared combined androgen blockade [...]
There was just a release of some of the data from the on-going review sipuleucel-T, or Provenge, in men with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic prostate cancer. The data wes presented by Oregon Health & Realm University Cancer [...]
There is some good news on the horizon, or at least we are setting up for the possibility of some future good news. Coming off of the recent news about the very successful phase II trial of CB7630 (abiraterone acetate), Cougar Biotechnology, Inc. has reached agreement with the FDA under a special protocol assessment (SPA) [...]
Researchers at Purdue have developed what they have described as prostate cancer “homing device.” They believe that this treatment modality can improve detection, and allow for the first targeted treatment of prostate cancer. The researchers have synthesized a molecule that finds and penetrates only prostate cancer cells. They have also created imaging agents and therapeutic [...]
Selenium is one of those supplements that were are told is good for us and then we are told it is bad for us. Every six months to a year the story and the recommendations seem to change. According to a study by researchers at Dana-Farber Cancer Institute the University of California, San Francisco higher [...]